Compare HubSpot Inc (HUBS) vs Twist Bioscience Corp (TWST) Price & Performance

HubSpot (HUBS) trades at $215.91, up 2.64% today but remains in a bearish technical trend. The company reported strong Q2 2026 earnings with EPS of $3.26 beating estimates, but lowered customer growth guidance to 5,000-6,000 per quarter. Revenue grew 20% year-over-year to $3.13 billion in 2025, with net income improving to $45.91 million. However, the stock faces headwinds from AI transition costs and a securities fraud investigation announced on August 10, 2026.

Despite near-term challenges, HubSpot maintains strong fundamentals with 76.6% analyst buy ratings and a $233.93 consensus target. The AI pivot creates execution risk but offers long-term growth potential. Key risks include customer acquisition slowdown, competitive pressures, and legal uncertainties. Current valuation at 78.5x P/E requires sustained execution for further upside.

TWST is trading at $124.88, up 7.96% in the last 24 hours, near its pivot point of $121 with resistance at $129. The stock shows strong technical momentum with bullish moving averages, though RSI levels indicate overbought conditions. Revenue growth is robust, with fiscal 2026 Q3 revenue up 23% year-over-year to $118.4 million, but the company remains unprofitable with a net income margin of -31.66% and negative cash flow from operations. Recent news highlights an upsized $300 million public offering and expansion in AI-driven drug discovery.

The outlook for TWST is mixed; bullish analyst sentiment and AI growth potential are offset by persistent losses and high valuation multiples. Investment opportunity lies in sustained revenue expansion and path to profitability, but risks include cash burn, competitive pressures, and execution challenges in scaling operations. The stock's current price exceeds the consensus target of $106.14, suggesting limited near-term upside based on fundamentals.